Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 2/20 | 0.54 |
| ▸ | AR | P10275 | 6/20 | 0.52 |
| ▸ | PGR | P06401 | 5/20 | 0.52 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | ESR1 | P03372 | 2/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | SERPINA6 | P08185 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14200096 | 1.00 | CYP17A1 (0.54) | CYP17A1ARPGRNR3C2MAPT | |
| SCHEMBL29519614 | 1.00 | CYP17A1 (0.54) | CYP17A1ARPGRNR3C2MAPT | |
| SCHEMBL3750546 | 1.00 | CYP17A1 (0.54) | CYP17A1ARPGRNR3C2MAPT | |
| SCHEMBL13139936 | 1.00 | CYP17A1 (0.54) | CYP17A1ARPGRNR3C2MAPT | |
| SCHEMBL17302786 | 1.00 | CYP17A1 (0.54) | CYP17A1ARPGRNR3C2MAPT | |
| SCHEMBL13397495 | 1.00 | CYP17A1 (0.54) | CYP17A1ARPGRNR3C2MAPT | |
| SCHEMBL12437208 | 1.00 | CYP17A1 (0.54) | CYP17A1ARPGRNR3C2MAPT | |
| SCHEMBL8843324 | 1.00 | CYP17A1 (0.54) | CYP17A1ARPGRNR3C2MAPT | |
| SCHEMBL11747587 | 0.89 | AR (0.48) | CYP17A1ARPGRNR3C2MAPT | |
| SCHEMBL24711581 | 0.86 | MAPT (0.49) | CYP17A1ARPGRNR3C2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230227492-A1 | MONOMERIC AND OLIGOMERIC COMPOUND EMBODIMENTS AS CONTRACEPTIVES AND THERAPIES AND METHODS OF MAKING AND USING THE SAME | THE USA AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2023-07-20 | — | — | US | disclosed |
| US-20230227492-A1 | MONOMERIC AND OLIGOMERIC COMPOUND EMBODIMENTS AS CONTRACEPTIVES AND THERAPIES AND METHODS OF MAKING AND USING THE SAME | THE USA AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2023-07-20 | — | — | US | disclosed |
| WO-2021252761-A2 | MONOMERIC AND OLIGOMERIC COMPOUND EMBODIMENTS AS CONTRACEPTIVES AND THERAPIES AND METHODS OF MAKING AND USING THE SAME | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2021-12-16 | — | — | WO | disclosed |
| EP-1918295-B1 | Process and intermediates for the production of 7-substituted antiestrogens | ASTRAZENECA AB (SE) | 2016-04-06 | — | — | EP | disclosed |
| WO-2015181116-A1 | PROCESS AND INTERMEDIADES FOR THE PREPARATION OF 7-ALKYLATED STEROIDS | CRYSTAL PHARMA, S.A.U. (ES) | 2015-12-03 | — | — | WO | disclosed |
| EP-1608670-B1 | PROCESS FOR THE PRODUCTION OF TIBOLONE | RESOLUTION CHEMICALS LTD (GB) | 2013-09-11 | — | — | EP | disclosed |
| EP-2497776-A2 | Process for the production of tibolone | Resolution Chemicals Limited (GB) | 2012-09-12 | — | — | EP | disclosed |
| EP-1436256-B1 | PREPARATION PROCESS OF SOME HALOGENO-SUBSTITUTED MONOSULFIDES AND THEIR HYDROXY-MONOSULFIDE OR ISOTHIOURONIUM BROMIDE EQUIVALENTS AS INTERMEDIATES | ASTRAZENECA AB (SE) | 2011-08-10 | — | — | EP | disclosed |
| US-7947667-B2 | Aromatization; hydrolysis; deblocking, deprotecting; oxidation; for production of fulvestrant | ASTRAZENECA AB (SE) | 2011-05-24 | — | — | US | disclosed |
| US-7947667-B2 | Aromatization; hydrolysis; deblocking, deprotecting; oxidation; for production of fulvestrant | ASTRAZENECA AB (SE) | 2011-05-24 | — | — | US | disclosed |
| US-7884222-B2 | protecting the 17-hydroxy group and the 3-keto group of nandrolone, then halogenating, methylating, isomerizing, dehydrogenating, reducing, oxidizing, ethynylating and deprotecting to form 17 beta -hydroxy-7 alpha -methyl-19-nor-17 alpha -pregn-5(10)-ene-20-yne-3-one | RESOLUTION CHEMICALS LIMITED (GB) | 2011-02-08 | — | — | US | disclosed |
| US-7884222-B2 | protecting the 17-hydroxy group and the 3-keto group of nandrolone, then halogenating, methylating, isomerizing, dehydrogenating, reducing, oxidizing, ethynylating and deprotecting to form 17 beta -hydroxy-7 alpha -methyl-19-nor-17 alpha -pregn-5(10)-ene-20-yne-3-one | RESOLUTION CHEMICALS LIMITED (GB) | 2011-02-08 | — | — | US | disclosed |
| US-20090062236-A1 | Programmable genotoxic agents and uses therefor | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2009-03-05 | — | — | US | disclosed |
| EP-1328538-B1 | PROCESS AND INTERMEDIATES FOR THE PRODUCTION OF 7-SUBSTITUTED ANTIESTROGENS | ASTRAZENECA AB (SE) | 2008-08-06 | — | — | EP | disclosed |
| US-7323602-B2 | Preparation process of some halogeno-substituted monosulfides and their hydroxy-monosulfide or isothiouronium bromide equivalents as intermediates | ASTRAZENECA AB (SE) | 2008-01-29 | — | — | US | disclosed |
| US-7169611-B2 | Programmable genotoxic agents and uses therefor | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2007-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230227492-A1 | MONOMERIC AND OLIGOMERIC COMPOUND EMBODIMENTS AS CONTRACEPTIVES AND THERAPIES AND METHODS OF MAKING AND USING THE SAME | SHBG, CYP19A1, GNRHR | CYP17A1 18/4885AR 7/4885PGR 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.